POST-ASH 2019UPDATES IN LYMPHOMA

Noémie Lang

JOURNEY LOGBOOK

• AIM for the stars

• FL on Target

• The Future is “BITE”

AIM for the stars

Three Year Update of the Phase IIABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study

Sasanka M. Handunnetti, Mary Ann Anderson, Kate Burbury, Rodney J. Hicks, Besiat Birbirsa, B.N.,Mathias Bressel, Juliana Di Iulio, David Alan Westerman, Stephen Lade, Rishu

Agarwal, Mark A. Dawson, Sarah-Jane Dawson, Rachel Koldej, David Ritchie, John F. Seymour, Andrew W. Roberts, Constantine S. Tam

Background

Ph 2 Ibrutinib in rrMCL: PFS Ph 1 Venetoclax in rrMCL: PFS

Wang et al, NEJM 2013; 369:507-516.Davids et al, Blood 2018; 132 (Supp 1):2883.

ORR 68%CRR 21%

mPFS 13.9 mo

ORR 75%CRR 21%

mPFS 11.3 mo

Study Design & Objectives• Investigator-initiated single-group Phase 2 study of

Venetoclax and Ibrutinib combination in R/R MCL

Endpoints:• CRR at week 16• ORR, MRD- rate, PFS,

OS, DOR, TTP

Baseline CharacteristicsCharacteristics (N 24) Value

Age (years), median (range) 68 (47-81)

Male 88%

No prior therapy for MCL 4%

Previously treated for MCL- Lines of prior therapy, median (range)- Prior autologous stem cell transplantation- No response (<PR) to last treatment

96%2 (1-6)

29%48%

ECOG 0-1 79%

B symptoms 17%

BM involvement 54%

Bulk (5-10 cm / >10 cm) 17% / 8 %

MIPI (Low / Intermediate / High) 4% 21% 75%

Blastoid or pleomorphic morphology (N21) 5%

Ki67 ≥ 30% (N 21) 43%

TP53 status (mut+/del+ ; mut+ del- ; del+/mut-) 17% / 29% / 4%

NF-KB pathway mutations (CARD11, BIRC3, TRAF2) 25%

Tumor lysis category (Low / Intermediate / High) 46% / 25% / 29%

Primary Analysis

Tam et al, NEJM 2018; 378:1211-1223

• 59% CR/CRu and 75% ORR by CT• 62% CRR and 71% ORR by PET

Primary Analysis

Tam et al, NEJM 2018; 378:1211-1223

• 67% BM MRD- by flow cytometry (N=19)• 38% PB MRD- by PCR (N=16)

• 59% CR/CRu and 75% ORR by CT• 62% CRR and 71% ORR by PET/CT

Safety AnalysisAdverse Events Any Grade

N 24 (%)Grade >3N 24 (%)

Any adverse event 24 (100) 17 (71)

Diarrhea 20 (83) 3 (12)

Fatigue 18 (75) 0

Nausea / Vomiting 17 (71) 0

Bleeding, bruising, postoperative hemorrhage 13 (54) 1 (4)

Musculoskeletal or connective tissue pain 12 (50) 1 (4)

Neutropenia 8 (33) 8 (33)

Anemia 7 (29) 3 (12)

Thrombocytopenia 5 (21) 4 (17)

Tumor lysis syndrome 2 (8) 2 (8)

Atrial fibrillation 2 (8) 2 (8)

Safety AnalysisAdverse Events Any Grade

N 24 (%)Grade >3N 24 (%)

Any adverse event 24 (100) 17 (71)

Diarrhea 20 (83) 3 (12)

Fatigue 18 (75) 0

Nausea / Vomiting 17 (71) 0

Bleeding, bruising, postoperative hemorrhage 13 (54) 1 (4)

Musculoskeletal or connective tissue pain 12 (50) 1 (4)

Neutropenia 8 (33) 8 (33)

Anemia 7 (29) 3 (12)

Thrombocytopenia 5 (21) 4 (17)

Tumor lysis syndrome 2 (8) 2 (8)

Atrial fibrillation 2 (8) 2 (8)

Serious Adverse Events N 24 (%)

Diarrhea 3 (12)

Tumor lysis syndrome 2 (8)

Atrial fibrillation 2 (8)

Pyrexia 2 (8)

Pleural effusion 2 (8)

Cardiac failure 1 (4)

Soft tissue infection 1 (4)

3 years UPDATE• Within 56 weeks: dose

adjustment performed in 15 patients

• New AE: 2 therapy-related MDS

Cohort Event History

Agarwal et al, Nat Med 2019; 25:119-129

N 24

• Whole Cohort• mFU 37.5 months• 13 deaths (8 PD)• 5 CR/MRD- on

“holiday” (mFU18.5 months)

• TP53 subset• ORR & CRR 50%• DOR 12-38 months

Duration of Response & Time to Progression

Estimated DOR at 30 months 74% Estimated TTP at 30 months 60%

Progression Free Survival & Overall Survival

Median OS 32 months (95% CI 27-NE)Median PFS 29 months (95% CI 13-NE)

Conclusions

• Ibrutinib & Venetoclax combination is safe and leads to

durable responses in R/R MCL

• mPFS 29 months, mOS 32 months

• Treatment cessation is feasible for MRD-CR

• Further prospective evaluation required (Ph 3 SYMPATICO)

FL on Target

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in

Patients With Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, Herve Tilly, Aristeidis Chaidos, Tycel J. Phillips, Vincent Ribrag, Philip Campbell, Damaj Gandhi Laurent, Wojciech Jurczak, Pamela McKay, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib and

Gilles A. Salles

• EZH2 is an epigenetic regulator of gene expression and cell fate decisions• EZH2 is required for normal B-cell biology and germinal center formation

Background

Adapted from Gan et al, Biomark Res 2018; Beguelin et al, Cancer Cell 2013; Bödor et al, Blood 2013; Italiano et al Lancet Oncol 2018;

Morschhauser et al, Hematol Oncol 2017

Histone & non-histone methylation

Transcription factors co-activationOFF

OncogeneTumor suppressorImmune Evasion

EZH2 ↓Naive

Dark Light Plasma

Memory

Apoptosis

• EZH2 biology is relevant in mutant (MT) and wild-type(WT) FL• EZH2 gain of function mutations ~ 20% FL

Background

Adapted from Gan et al, Biomark Res 2018; Beguelin et al, Cancer Cell 2013; Bödor et al, Blood 2013; Italiano et al Lancet Oncol 2018;

Morschhauser et al, Hematol Oncol 2017

• Oncogene• Tumor suppressor• Immune Evasion

Histone & non-histone methylation

Transcription factors co-activation

ON

OncogeneTumor suppressorImmune Evasion

EZH2 ↑↑

Gain of function Alteration EZH2

Naive

Dark Light Plasma

Memory

Apoptosis

Malignant B-cell

Background

Adapted from Gan et al, Biomark Res 2018; Beguelin et al, Cancer Cell 2013; Bödor et al, Blood 2013; Italiano et al Lancet Oncol 2018;

Morschhauser et al, Hematol Oncol 2017

• Tazemetostat is a selective, first-in class, oral inhibitor of EZH2

• Histone & non-histone methylation

• Co-activation for transcription factors

Histone & non-histone methylation

Transcription factors co-activation

EZH2 ↓

Gain of function Alteration

TAZEMETO

STAT

OncogeneTumor suppressorImmune Evasion

OFF

Naive

Dark Light Plasma

Memory

Apoptosis

Malignant B-cell

Study Design & Objectives

• Multicentric Phase 2 study of Tazemetostat in FL progressing after at least 2 lines of prior therapies including an anti-CD20

End points:• ORR (Cheson 2007)• DOR, PFS, Safety, PK

FL, EZH2 MT (n=45)

FL, EZH2 WT (n=45b)Analyzed of

archival tissue for EZH2 hot

spot activating mutations

Tazemetostat 800 mg BID

Treatment continues until

progressive disease or

withdrawal

Response assessed every 8

weeks using 2007 IWG-NHL criteria

SCRE

ENIN

G

ELIG

IBIL

TY, E

NRO

LLM

ENT

COHO

RT A

SSIG

NM

ENT

END

OF

TRIA

L FO

LLO

W-U

P

Baseline Characteristics

Characteristics MT EZH2 N 45 (%) WT EZH2 N 54 (%) Age (years), median (range) 62 (38–80) 60.5 (36–87)Male / Female 19 (42.2) 26 (57.8) 34 (63) 20 (37)ECOG (0 / 1 / 2 / missing) 21 (46.7) 24 (53.3) 0 0 26 (48.1) 23 (42.6) 4 (7.4) 1 (1.9)Prior lines of anticancer therapy1234≥5Median (range)

2 (4.4)22 (48.9)10 (22.2)4 (8.9)7 (15.6)2 (1-11)

1 (1.9)16 (29.6)11 (20.4)10 (18.5)16 29.6)3 (1–8)

Refractory to Rituximab based-regimen 22 (48.9) 32 (59.3)Refractory to last regimen 22 (48.9) 22 (40.7)Prior HSCT 4 (8.9) 21 (39)POD 24 19 (42.2) 32 (59.3)GELF Criteria 31 (68.9) 40 (74.1)

Safety Analysis

• Good tolerance profile• Low rate of grade ≥3 AEs • 8% discontinuation• 9% dose reduction• 27% dose interruption• No Treatment-related

death

CategoryAEs ≥ 10% patients (N=99)

All (%) Grade ≥3 (%)Nausea 19 0Asthenia 15 1Diarrhea 12 0Fatigue 12 1Alopecia 14 0Cough 2 0Upper resp. tract infection 1 0Bronchitis 3 0Anemia 9 2Abdominal pain 2 0Headache 5 0Vomiting 6 0Back pain 0 0Pyrexia 2 0Thrombocytopenia 8 3

TAZEMETOSTAT

Response rate in MT EZH2 & WT EZH2 CohortsMT EZH2 (N45)

WT EZH2 (N54)

98% evidence of tumor reduction (IRC)

71% evidence of tumor reduction (IRC)• High concordance between Investigator and IRC (86%)

• Clinical Activity in High-Risk Subgroups (rituximab refractory, POD24)

MT EZH2 (45) WT EZH2 (54)Investigator IRC Investigator IRC

ORR (%) 78 69 33 35CR (%) 9 13 6 4PR (%) 69 56 28 31SD(%) 22 29 30 33PD(%) 0 2 30 22NE (%) 0 0 7 9

MT EZH2 (N45)

WT EZH2 (N54)* Median DOR continues to mature for the MT EZH2 cohort.

• Time to response ~4 months in both cohorts• 17% MT and 18% WT patients showed

clinical benefit and continued therapy beyond PD

MT EZH2 (45) WT EZH2 (54)Investigator IRC Investigator IRC

mDOR(months)

8.3*(5.5, 13.8)

10.9*(7.2, NE)

14.7(7.6, NR)

13.0(5.6, NR)

Ongoing N (%) 13 (29) 0

mFU(months) 22.0 (2.8 – 43.5) 35.9 (0.3-48.8)

Duration of Response in MT & WT EZH2 Cohorts

PFS in MT EZH2 and WT EZH2 Cohorts

WT EZH2 (N54)MT EZH2 (N45)

Median PFS was 13.8 and 11.1 months for MT and WT EZH2 cohorts

PFS in MT EZH2 and WT EZH2 Cohorts

WT EZH2 (N54)MT EZH2 (N45)

Median OS was Not Reached for both cohorts

Conclusions

• Tazemetostat is an oral EZH2 inhibitor with a good tolerance profile

• Tazemetostat is highly active in R/R follicular lymphoma

• ORR of 69% in MT EZH2 (35% in WT EZH2)• Median PFS of 13.8 months in MT EZH2 (11.1 months in WT EZH2)

• Durable responses, also in high-risk subgroups

• Tazemetostat is a good candidate for future combination studies

The Future is “BITE”

Background

Rivas-Delgado et al, BJH 2019; 184(5):753-759.Crump et al, Blood 2017; 130(16):1800-1808.

Outcome of R/R FL &DLBCL

Background

Lymphocyte T

Malignant B lymphocyte

Bispecific antibodies (BITEs) = Novel therapeutic strategy

Baeuerle et al, Cancer Research 2009 Goebeler et al, JCO 2016

CD20

CD3

Background

Lymphocyte T

Malignant B lymphocyte

Cytolysis

Baeuerle et al, Cancer Research 2009 Goebeler et al, JCO 2016

CD20

CD3 • Promote T-cells activation & expansion.• Induce “immunological synapse” between T

cell - malignant CD20+ B cell → Delivery of cytotoxic proteins & apoptosis induction

• Remain active in presence of CD20 antibody “mabs”

Bispecific antibodies (BITEs) = Novel therapeutic strategy

ANTI CD3/CD20 BITEs

Sun et al. Sci Transl Med 2015Budde et al. ASH 2018; 3 Bartlett et al. ASCO 2019

“OFF-THE-SHELF” = NO DELAY

Mosunetuzumab Induces Complete Remissions In Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant To Or Relapsing After

Chimeric Antigen Receptor T-cell (CAR-T) Therapies, And Is Active In Treatment Through Multiple Lines

Stephen J Schuster, Nancy L Bartlett, Sarit Assouline, Sung-Soo Yoon, Francesc Bosch, Laurie H Sehn, Chan Yoon Cheah, Mazyar Shadman, Gareth P Gregory, Matthew Ku, Michael C Wei, Shen Yin, Antonia Kwan, Kasra Yousefi, Genevive Hernandez, Chi-Chu

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)

Rajat Bannerji, John N. Allan, Jon E. Arnason, Jennifer R. Brown, Ranjana H Advani, Jeffrey A. Barnes, Stephen M. Ansell, Susan M. O'Brien, Julio Chavez, Johannes Duell, Peter Martin, Robin M. Joyce, Robert Charnas, Srikanth R. Ambati, Lieve Adriaens, Pharm, Melanie Ufkin, Min Zhu, Jingjin Li, Peter Gasparini, Anfal Ibrahim, Vladimir Jankovic, Nathalie Fiaschi, Olulanu Aina, Wen Zhang, Raquel P. Deering, Sara Hamon, Gavin Thurston, Andrew J. Murphy, David M. Weinreich, George D.

Yancopoulos, Israel Lowy, David Sternberg,Max S. Topp

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3xCD20) in B-cell Non-Hodgkin Lymphoma

Pieternella Lugtenburg, Rogier Mous, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, Kim Linton, Simon Rule, Roberto S Oliveri, Dena DeMarco, Ida H Hiemstra, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings

Mosunetuzumab Induces Complete Remissions In Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant To Or Relapsing After

Chimeric Antigen Receptor T-cell (CAR-T) Therapies, And Is Active In Treatment Through Multiple Lines

Stephen J Schuster, Nancy L Bartlett, Sarit Assouline, Sung-Soo Yoon, Francesc Bosch, Laurie H Sehn, Chan Yoon Cheah, Mazyar Shadman, Gareth P Gregory, Matthew Ku, Michael C Wei, Shen Yin, Antonia Kwan, Kasra Yousefi, Genevive Hernandez, Chi-Chu

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL)

Rajat Bannerji, John N. Allan, Jon E. Arnason, Jennifer R. Brown, Ranjana H Advani, Jeffrey A. Barnes, Stephen M. Ansell, Susan M. O'Brien, Julio Chavez, Johannes Duell, Peter Martin, Robin M. Joyce, Robert Charnas, Srikanth R. Ambati, Lieve Adriaens, Pharm, Melanie Ufkin, Min Zhu, Jingjin Li, Peter Gasparini, Anfal Ibrahim, Vladimir Jankovic, Nathalie Fiaschi, Olulanu Aina, Wen Zhang, Raquel P. Deering, Sara Hamon, Gavin Thurston, Andrew J. Murphy, David M. Weinreich, George D.

Yancopoulos, Israel Lowy, David Sternberg,Max S. Topp

First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3xCD20) in B-cell Non-Hodgkin Lymphoma

Pieternella Lugtenburg, Rogier Mous, Michael Roost Clausen, Martine E.D. Chamuleau, Peter Johnson, Kim Linton, Simon Rule, Roberto S Oliveri, Dena DeMarco, Ida H Hiemstra, Guang Chen, Ada Azaryan, Manish Gupta, Tahamtan Ahmadi, Martin Hutchings

Parameters MOSUNETUZUMAB REGN 1979 GEN3013Trial design 1/1B (NCT03677141) 1 (NCT02290951) 1/2 (NCT03625037 )

Number patients 270 96 18

Structure IgG1 IgG4 IgG1

Dose ranging Esc..: 0.05 to 2.8mg Exp.: 0.4/1/2.8-1/2/40.5mg (step-up dose)

0.03-80 mg flat dose 0.4 µg

Route IV IV SC

Schedule therapy Cycle 1 D1/8/15; q3w cycle 2-8• CR : discontinuation• PR/SD: continuation up to 17 cycles

q1w x 12+ q2w x 12

Cycle 1–2: q1wCycles 3-6: q2w

Q4w until PD / toxicity

Median dose (range) 5 (range 3-14) 9 (1-24) 5 (1-14)

Age (years, range) 62 (19-96) 67 (30-88) 58.5 (21-80)

Male 172 (63.7%) 77 (70%) 13 (72%)

Disease entitiesDLBCLFL G1-3A (tFL)MCLMZLOthers (FL G3B/unknown, WM)

11782 (32)

23NA11

5325666

14NANANANA

Prior line of therapy (range) 3 (1-14) 3 (1-11) 1 (1-11)

CD3/CD20 BITEs Overview

• Single-group Phase 1/1B dose-escalation and expansion study of Mosunetuzumab in R/R B-NHL

• IgG1 monoclonal antibody• IV outpatient administration• Cycle 1 step-up dosing then fixed dose • Initial treatment = 8 cycles

• CR: treatment discontinued• PR/SD: continued for up to 17 cycles

• Retreatment allowed if initial CR and subsequent relapse

Study Design & Objectives

Cycle 1 Cycle 2 Cycle 3

21 days

D1 D8 D15 D1 D1

Endpoints:• Safety, MTD, best ORR

Baseline Characteristics

N=270Median age, years (range) 62 (19–96)Male 172 63.7%)ECOG PS 1 at baseline 164 (61.2%)Aggressive NHL 180 (66.7%)

DLBCL 117 (43.3%)trFL 32 (11.9%)MCL 23 (8.5%)Other 8 (3.0%)

Indolent NHL 85 (31.5%)FL 82 (30.4%)Other 3 (1.1%)

Median prior systemic therapies (N=268) (range) 3 (1–14)Prior CAR-T therapy 30 (11.1%)Prior autologous SCT 77 (28.5%)Refractory to last prior therapy 194 (71.9%)Refractory to prior anti-CD20 therapy 233 (86.3%)

Prior CAR-T therapy (N=30)• 17 DLBCL, 8 tFL, 5 FL• Median 5 lines of prior systemic therapies

(range 3–14)• 96.7% refractory to anti-CD20• 83.3% refractory to last therapy• 73.3% refractory to CAR-T

Safety AnalysisPatients with ≥1 AE (%)AE * 94.4

Related AE 70.4Gr 3–5 AE 63

Related Gr 3–5 AE 34.1Cytokine release syndrome § 1.1Neurological AE # 3.7Serious AE 36.9

Related serious AE 18.9

Fatal AE (not including progression) † 1.9

Related AE leading to treatment withdrawal 2.6

Related AE leading to dose interruption/modification 20

All Gr AEs in >15% pts (%)

Cytokine release syndrome § 28.9

Neutropenia‡ 24.1

Fatigue 20.4

Hypophosphatemia 19.3

Diarrhea 16.7

Pyrexia 16.3

Headache 15.6

Nausea 15.2

Gr 3–4 AEs in >5% pts (%)

Neutropenia ‡ 21.8

Hypophosphatemia 13.3

Anemia 8.9

• 95% AEs occurred in Cycle 1; no cumulative or chronic toxicity• † Candida sepsis, Bowel perforation, pneumonia, volvulus, sepsis• § According to Lee criteria• #According to CTCAE v4.0• ‡ Neutropenia events were responsive to G-CSF, Low rate of FN (3.3%)

Lee et al. Biol Blood Marrow Transplantation 2019

Responses in Aggressive B-NHL

ORR 46/124 (37.1%)CRR 24/124 (19.4%)

Response Rate & Duration in Aggressive B-NHL

• 70.8% of CR remain in remission(up to 16 months off therapy)

• CR observed in high-risk subgroups

ORR CRAggressive NHL (N=124) 37.1% 19.4%

DLBCL/tFL ≥ 2 lines (N=98) 37.8% 20.4%

• Anti-CD20 Refractory (N=88) 36.4% 20.5%

• With prior auto SCT (N=32) 53.1% 34.3%

Prior CAR-T ORR CRAll (N=18) 7 4• DLBCL (N=9) 2 2• tFL (N=5) 1 0• FL (N=4) 4 2

Responses in Indolent B-NHL

ORR 42/67 (72.7%)CRR 29/67 (43.3%)

ORR CR

Indolent NHL (N=67) 62.7% 43.3%

FL after ≥ 2 lines (N=61) 63.9% 44.3%

• Double Refractory (N=43) 65.1% 44.2%

• History of POD24 (N=33) 60.6% 42.4%

• PI3KI refractory (N=9) 88.9% 77.8%

Response Rate & Duration in Indolent B-NHL

• 82.8% of CR remain in remission (up to 26 months off therapy)

• CR observed in high-risk subgroups

Conclusions

• Mosunetuzumab monotherapy exhibits a promising risk-benefit profile in R/R B-NHL

• Achieves CR in high-risk patients (including post CAR-T)• CR are maintained after completion of therapy • Re-treatment is feasible

• Single-agent and combination studies are ongoing, including studies in untreated patients

TAKE HOME MESSAGES

• IBRUTINIB + VENETOCLAX combination is tolerable and achieve a high rate of complete and durable responses in MCL (CRR 62%), phase 3 SYMPATICO is ongoing

• TAZEMETOSTAT is a well tolerated first-in-class oral EZH2 inhibitor showing activity in both mutated and unmutated FL

• Anti CD20/CD 3 BITEs demonstrated an acceptable safety profile and impressive ORR/CRR in heavily pretreated CD20+ NHL including post-CAR T-cell relapses

TAKE HOME MESSAGES

• IBRUTINIB + VENETOCLAX combination is tolerable and achieve a high rate of complete and durable responses in MCL (CRR 62%), phase 3 SYMPATICO is ongoing

• TAZEMETOSTAT is a well tolerated first-in-class oral EZH2 inhibitor showing activity in both mutated and unmutated FL

• Anti CD20/CD 3 BITEs demonstrated an acceptable safety profile and impressive ORR/CRR in heavily pretreated CD20+ NHL including post-CAR T-cell relapses

TAKE HOME MESSAGES

• IBRUTINIB + VENETOCLAX combination is tolerable and achieve a high rate of complete and durable responses in MCL (CRR 62%), phase 3 SYMPATICO is ongoing

• TAZEMETOSTAT is a well tolerated first-in-class oral EZH2 inhibitor showing activity in both mutated and unmutated FL

• Anti CD20/CD 3 BITEs demonstrated an acceptable safety profile and impressive ORR/CRR in heavily pretreated CD20+ NHL including post-CAR T-cell relapses

QUESTION

Tazemetostat is a new targeted iv agent effective

A) only in EZH2 mutated relapsed/refractory follicular lymphomaB) in both EZH2 mutated and unmutated relapsed/refractory follicular lymphomaC) only in EZH2 mutated relapsed/refractory mantel cell lymphomaD) in both EZH2 mutated and unmutated newly diagnosed follicular lymphoma

Thank YOU

“Failure is NOT an option.SUCCESS is just a Process!”